Cerebrospinal Fluid Defines SOD1 as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy

BACKGROUND: Therapies designed to decrease SOD1 are currently in clinical trial for patients with superoxide dismutase (SOD1)-linked Familial Amyotrophic Lateral Sclerosis (ALS), OBJECTIVE: To determine whether SOD1 protein in cerebral spinal fluid (CSF) may be a pharmacodynamic marker and whether S...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Winer, Leah, B.A., Srinivasan, Dushyanth, B.A., Chun, Seung, B.A., Lacomis, David, Jaffa, Matthew, B.A., Fagan, Anne, Holtzman, David M., Wancewicz, Ed, B.S., Bennett, C.F., Bowser, Robert, Cudkowicz, Merit, Miller, Timothy M.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3812918/
https://ncbi.nlm.nih.gov/pubmed/23147550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2013.593
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars